Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; Association with proteasome and calpain activities

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 4, 2013, Pages 625-633

  Spirina, Liudmila V ^a   Kondakova, Irina V ^a   Choynzonov, Evgeny L ^a   Chigevskaya, Svetlana Y ^a   Shishkin, Dmitry A ^a   Kulbakin, Denis Y ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

Author keywords

Calpain; HIF 1; Proteasome; Squamous cell carcinoma of head and neck; Transcription factors NF kB p65 and p50; VEGF

Indexed keywords

20S PROTEASOME; 26S PROTEASOME; CALPAIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CALPAIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NF-KAPPA B; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876413825     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1366-0     Document Type: Article

References (40)

1. Abramova EB, Astakhova TM, Erokhov PA, Sharova NP (2004) Multiple forms of the proteasomes and some approaches to their separation. Izv Akad Nauk Ser Biol 2:150-156
2. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16(4):433-443
3. An J, Rettig MB (2005) Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 25:7546-7556
4. An J, Rettig MB (2007) Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6(1):61-69
5. Arlt A, Bauer I, Shagmayer C, Telep J et al (2009) Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 28(45):3983-3996
6. Baldwin AS (1996) The NF-kappa B and I-kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649-683
7. Ben-Shahar S, Komlosh A, Nadav E et al (1999) 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. The J of Biol Chem 274(31):21963-21972
8. Chen C, Seth AK, Aplin AE (2006) Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res 4:695-707
9. Chen Z, Rickel JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yen NT, Van Waes C (2008) Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 7(7):1949-1960
10. Conner JR, Smirnova II, Moseman AP, Poltorak A (2010) IRAK1BP1 inhibits inflammation by promoting nuclear translocation of NF-kappaB p50. Proc Natl Acad Sci USA 107(25):11477-11482
11. Goldberg AL (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35:12-17
12. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83:731-801
13. Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennik JR, Yewdell JW (2010) Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 184(8):4115-4122
14. Jiang LZ, Wang P, Deng B, Huang C, Tang WX, Lu HY, Chen HY (2011) Overexpression of forkhead box M1 transcription factor and nuclear factor-kB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol 42(8):1185-1193
15. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I (2011) Bortezomib induces nuclear translocation of IkBα resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 9(2):183-194
16. Kelvin JAD, Reshma S (2006) Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. Neurology 66:93-96
17. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13:7388-7393
18. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM (2005) Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB J 19(6):650-652
19. Laemmi UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685
20. Li C, Li R, Grandis JR, Johnson DE (2008) Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 7(6):1647-1655
21. Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY (2010) Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285(21):16096-16104
22. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z (2008) Hypoxia inducible factor-1alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 28:1659-1666
23. Linder C, Linder S, Munck-Wikland E, Auer G, Aspenblad U (1998) Evaluation of tissue and serum VEGF in patients with head and neck carcinoma. Angiogenesis 2:365-372
24. Marui N, Medford RM, Ahmad M (2005) Activation of RelA homodimers by tumor necrosis factor alpha: a possible transcriptional activator in human vascular endothelial cells. Biochem J 390:317-324
25. Molitoris KH, Kazi AA, Koos RD (2009) Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology 150(12):5405-5414
26. Moorty AK, Savinova OV, Ho JQ, Wang VY, Vu D, Ghosh G (2006) The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO J 25(9):1945-1956
27. Reichart J, Welter C, Mitschele T, Classen U, Meineke V, Seifert M (2003) Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. J Pathol 199(4):509-516
28. Ridge JA, Glisson BS., Lango MN, Feigenberg S (2011) Head and neck tumors cancer management, 14th edn. http://cancernetwork.com/cancer-management/head- and-neck/article/10165/1802498 Accessed 2 November 2011
29. Sandmann S, Prenzel F, Shaw L, Schauer R, Unger T (2002) Activity profile of calpains I and II in chronically infarcted rat myocardium-influence of the calpain inhibitor CAL 9961. Br J Pharmacol 135(8):1951-1958
30. Smith IJ, Dodd SL (2007) Calpain activation causes a proteasome dependent increase in protein degradation and inhibits the Akt signaling pathway in rat diaphragm muscle. Exp Physiol 92(3):561-573
31. Sorimachi H, Hata S, Ono Y (2011) Calpain chronicle - an enzyme family under multidisciplinary characterization. Proc Jpn Acad Ser B Phys Biol Sci 87:287-327
32. Sorokin AV, Kim ER, Ovchinnikov LP (2009) Proteasome system of protein degradation and processing. Biochemistry (Mosc) 74(13):1411-1442
33. Spirina LV, Kondakova IV, Choinzonov EL, Sharova NP, Chigevskaya SY, Shishkin DA (2010) Activity and subunit composition of proteasomes in head and cervical squamous cell carcinomas. Bull Exp Biol Med 149(1):82-85
34. Spirina LV, Yunusova NV, Kondakova IV, Kolomiets LA, Koval VD, Chernyshova AL, Shpileva OV (2012a) Association of growth factors, HIF-1 and NF-kB expression with proteasomes in endometrial cancer. Mol Biol Rep 39(9):8655-8662
35. Spirina LV, Bochkareva NV, Kondakova IV, Kolomiets LA, Shashova EE, Koval VD, Chernyshova AL, Asadchikova ON (2012b) Regulation of insulin-like growth NF-kappa B proteasome system in endometrial cancer. Mol Biol (Mosk) 46(3):452-460
36. van Uden P, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412(3):477-484
37. Voutsadakis IA (2007) Pathogenesis of colorectal carcinoma and therapeutic implications: the role of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 11(2):252-337
38. Yan M, Xu Q, Zhang P, Zhou X, Chen W (2010) Correlation of NF-kB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer 10:437
39. Yue CX, Ma J, Zhou HJ (2011) The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors. Sichuan Da Xue Xue Bao Yi Xue Ban 42(4):445-501
40. Zhou J, Kohl R, Herr B, Frank R, Brune B (2006) Calpain mediates a von Hippel-Lindau protein-independent destruction of hypoxia-inducible factor -1α. Mol Biol Cell 17(4):1549-1558